Aurealis Pharma closes a CHF 5.6M investment in Series A financing to advance chronic wound and oncology lead products.

Finland Investments 25 August 2017
Share on FacebookShare on Twitter

Aurealis Pharma, a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing novel combination biologics for chronic inflammation and cancer, announced today the closing of CHF 5.6M ($5.8M) Series A funding.

The money comes from Swiss and foreign private investors, Finnvera plc and Tekes, and will enable Aurealis Pharma to advance its chronic wound treatment AUP-16 into clinical trial application (CTA) filing and its cancer lead candidate AUP-5550 into non-clinical safety and efficacy studies.

Aurelis Pharma, led by CEO Juha Yrjänheikki, was founded in the Finnish city Kuopio in 2010, and today operates from there and from Basel in Switzerland.